The ASH Annual Meeting virtual platform opens on Wednesday, December 4, 2024, to all attendees. Most sessions offered in San Diego will be broadcast simultaneously on the virtual platform. Once a session takes place, the platform will include an on-demand recording of the session. There are th...
Complimentaryaccess to the meeting’s virtual platform through January 1, 2025 (In-person registrants will have the option to extend their access to the annual meeting virtual platform for an additional fee). Hematology 2024, the ASH Education Program(digital only) Program notebook Access to the ...
Report from the ASH annual meeting. memo 17 (Suppl 5), 95–96 (2024). https://doi.org/10.1007/s12254-024-01018-z Download citation Accepted17 December 2024 Published24 January 2025 Issue DateDecember 2024 DOIhttps://doi.org/10.1007/s12254-024-01018-z Share this article Anyone you share...
2024 ASH Annual MeetingDaniela MarínLan-Lan SmithThe Lancet Haematology
Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss the biggest winner from the 2023 meeting.This is a modal window. The Playback API request failed for an unknown reason...
Joshua Richter, MD, led an enthusiastic panel with his colleagues in the multiple myeloma space following the 2023 ASH Annual Meeting and Exposition. The expert panel Joshua Richter, MD, led an enthusiastic panel with his colleagues in the multiple myeloma space...
(R/R) CD19-positive B-cell malignancies at the 2024 American Society of Hematology (ASH) Annual Meeting. Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for...
Merck, known as MSD outside of the United States and Canada, announced the presentation of findings from clinical trials and real-world studies at the upcoming 64th American Society of Hematology Annual Meeting from Dec. 10-13, 2022, ...
2.Wu P, et al. 2024 ASH. Poster 1575. https://annualmeeting.hematology.org/embed-app/243658 3.马萍,洪鸣.急性髓系白血病一线诱导方案相关进展[J/OL].南京医科大学学报(自然科学版),1-8[2024-12-20]. 4.王佳琦,盛新歌,马志豪,等.高危急性髓系白血病异基因造血干细胞移植后复发的防治[J].器官移植...
[10].https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-myelodysplastic-syndromes查询日期2025年1月10日 [11].DiNardo CD, et al. Blood Adv. 2024 Aug 13;8(15):4209-4220. [12].20...